P3.01-97 Which Is Better Prognostic Factor, PS, Inflammatory Marker, or PD-L1 Expression in Treating NSCLC With Nivolmab; A Retrospective Analysis

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1657
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

45. A Retrospective Assessment of PD-L1 Expression Rates in NSCLC

Pathology
Forensic MedicinePathology
2020English

MA11.06 Prognostic Value of Complement System in NSCLC and Its Association With PD-1 and PD-L1 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Prognostic Impact of Tumor Cell PD-L1 Expression and Immune Cell Infiltration in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

PD-L1 Expression in Inflammatory Myofibroblastic Tumors

Modern Pathology
Forensic MedicinePathology
2018English

PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2018English

P2.09-004 PD-L1 Protein Expression Is Negative Prognostic Factor in Malignant Pleural Mesothelioma in Central Europe

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

MA09.09 EBUS-TBNA in Assessing PD-L1 Expression in NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.04-13 PD-L1-Gene Expression by nCounter Correlates With PD-L1 Protein Expression in Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-115 Liposomal Paclitaxel Versus Gemcitabine: Which Is Better?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy